Barclays Maintains Overweight on Globus Medical, Raises Price Target to $93
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Overweight rating on Globus Medical (NYSE:GMED) and raises the price target from $85 to $93.
August 08, 2024 | 6:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Matt Miksic maintains an Overweight rating on Globus Medical and raises the price target from $85 to $93.
The Overweight rating and increased price target from a reputable analyst at Barclays is likely to positively influence investor sentiment and drive short-term price appreciation for GMED.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100